Portola Pharmaceuticals (Nasdaq: PTLA), announced that it has licensed lead development and commercial rights to its investigational agent andexanet alfa ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE